Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Omeprazole.

M J Langman1

  • 1Department of Medicine, Queen Elizabeth Hospital, Birmingham, UK.

Alimentary Pharmacology & Therapeutics
|August 1, 1991
PubMed
Summary
This summary is machine-generated.

Omeprazole effectively reduces stomach acid, offering significant benefits for esophageal reflux disease. While its advantages for ulcers are limited due to existing effective treatments, concerns about side effects and drug interactions appear minimal, though caution is advised.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology of cancer of the large intestine.

Proceedings of the Royal Society of Medicine·2010
Same author

Postmarketing surveillance of the safety of cimetidine: 15-year mortality report.

Pharmacoepidemiology and drug safety·2004
Same author

Which PPI?

Gut·2001
Same author

Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?

Pharmacoepidemiology and drug safety·2001
Same author

Heparin therapy for ulcerative colitis? Effects and mechanisms.

European journal of gastroenterology & hepatology·2001
Same author

Drug treatment of non-variceal upper gastrointestinal bleeding.

Bailliere's best practice & research. Clinical gastroenterology·2000
Same journal

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Alimentary pharmacology & therapeutics·2026
Same journal

Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.

Alimentary pharmacology & therapeutics·2026
Same journal

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Alimentary pharmacology & therapeutics·2026
Same journal

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.

Alimentary pharmacology & therapeutics·2026
Same journal

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: Interpreting P-CAB Superiority for Antithrombotic Gastroprotection Beyond Acid Suppression. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
See all related articles

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Omeprazole is a potent antisecretory medication.
  • Standard treatments for gastric and duodenal ulcers are highly effective.

Purpose of the Study:

  • To evaluate the benefits and risks of omeprazole.
  • To assess its efficacy in treating gastrointestinal conditions.

Main Methods:

  • Review of existing literature on omeprazole's clinical use.
  • Analysis of data regarding its antisecretory effects and adverse events.

Main Results:

  • Omeprazole shows clear advantages in managing esophageal reflux disease due to profound acid inhibition.
  • Benefits for gastric and duodenal ulcers appear marginal compared to standard therapies.

Related Experiment Videos

  • Concerns regarding ECL cell hyperplasia, carcinogenesis, and drug interactions are not strongly supported by evidence.

    • Conclusions:

    • Omeprazole is highly effective for esophageal reflux disease.
    • Its use in peptic ulcer disease may be limited.
    • Continued vigilance regarding its use is warranted despite a seemingly favorable safety profile.